Stock MBX MICROBIX BIOSYSTEMS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Microbix Biosystems Inc.

Equities

MBX

CA59501P1045

Biotechnology & Medical Research

Market Closed - Toronto S.E.
Other stock markets
 02:40:59 2024-05-24 pm EDT 		5-day change 1st Jan Change
0.32 CAD -1.54% Intraday chart for Microbix Biosystems Inc. -3.03% -17.95%
May. 15 Microbix Biosystems Up More Than 10% As Q2 Profit Grows On Higher Revenues; Says Stage Set For Record FY MT
May. 15 Transcript : Microbix Biosystems Inc., Q2 2024 Earnings Call, May 15, 2024

Business Summary

Microbix Biosystems Inc. is a Canada-based life science company, which develops and commercializes biological and technological solutions for human health and wellbeing. The Company manufactures a wide range of critical biological materials for the global diagnostics industry, mainly antigens for immunoassays and its laboratory quality assessment products (QAPs) that support clinical lab proficiency testing, enable assay development and validation, or help ensure the quality of clinical diagnostic workflows. It operates through two segments: the development, manufacturing and sales of products relating to the medical diagnostics industry, namely antigens as test ingredients, quality assessment products to help ensure the accuracy of test workflows and viral transport medium to enable collection of patient test samples and the development and commercialization of products or technologies such as Kinlytic. Its Kinlyti urokinase is a biologic thrombolytic drug used to treat blood clots.

Sales per Business

CAD in Million2022Weight2023Weight Delta
Antigens,Quality Assessment Products and DxTM
91.8 %
19 100.0 % 15 91.8 % -20.49%
Other (includes Kinlytic)
8.2 %
0 0.0 % 1 8.2 % +30,440.89%

Sales per region

CAD in Million2022Weight2023Weight Delta
North America
65.6 %
13 68.9 % 11 65.6 % -17.58%
Europe
34.4 %
6 31.0 % 6 34.4 % -4.05%
Other Foreign Countries
0.0 %
0 0.1 % 0 0.0 % -73.92%

Managers

Managers TitleAgeSince
Cameron Groome CEO
 Chief Executive Officer - 12-03-07
James Currie DFI
 Director of Finance/CFO - 16-10-31
Mark Luscher CTO
 Chief Tech/Sci/R&D Officer - -
Christopher Lobb CMP
 Compliance Officer 65 -
Kenneth Hughes CTO
 Chief Tech/Sci/R&D Officer - 94-12-31
Vaughn Embro-Pantalony BRD
 Director/Board Member 66 07-02-05
Philip Casselli SAM
 Sales & Marketing - 02-12-31

Members of the board

Members of the board TitleAgeSince
Mark Cochran BRD
 Director/Board Member - 90-09-30
Peter Blecher BRD
 Director/Board Member - 05-12-05
Cameron Groome CEO
 Chief Executive Officer - 12-03-07
Joseph Renner BRD
 Director/Board Member - 03-02-24
Martin Marino CHM
 Chairman - 09-02-16
Vaughn Embro-Pantalony BRD
 Director/Board Member 66 07-02-05
Jennifer Stewart BRD
 Director/Board Member - 22-03-29

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 136,917,006 117,695,402 ( 85.96 %) 0 85.96 %

Shareholders

NameEquities%Valuation
Joseph Renner
6.425 %
8,773,370 6.425 % 2 M $
Peter Blecher
2.668 %
3,643,704 2.668 % 892 707 $
Cameron Groome
1.937 %
2,645,500 1.937 % 648 148 $
Vaughn Embro-Pantalony
1.221 %
1,666,704 1.221 % 408 342 $
Martin Marino
0.8898 %
1,215,000 0.8898 % 297 675 $
UBS Asset Management (Canada) Inc.
0.5126 %
700,000 0.5126 % 171 500 $
LDIC, Inc.
0.4244 %
579,500 0.4244 % 141 978 $
Next Edge Capital Corp.
0.4028 %
550,000 0.4028 % 134 750 $
Mark Cochran
0.4023 %
549,277 0.4023 % 134 573 $
Philip Casselli
0.3819 %
521,486 0.3819 % 127 764 $

Company contact information

Microbix Biosystems, Inc.

265 Watline Avenue

L4Z 1P3, Mississauga

+

http://microbix.com
address Microbix Biosystems Inc.(MBX)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Other Biotechnology & Medical Research

Sales per Business

Sales per region

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.32 CAD
Average target price
0.8 CAD
Spread / Average Target
+150.00%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
MICROBIX BIOSYSTEMS INC. Stock Microbix Biosystems Inc.
-17.95% 32.07M
MODERNA, INC. Stock Moderna, Inc.
+67.53% 63.85B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-0.77% 41.83B
LONZA GROUP AG Stock Lonza Group AG
+44.47% 40.65B
CELLTRION, INC. Stock Celltrion, Inc.
-10.72% 27.12B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+13.30% 26.52B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-22.79% 18.69B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+4.70% 12.73B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+24.10% 12.11B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+27.41% 12.07B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. MBX Stock
  4. Company Microbix Biosystems Inc.